Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk's stock ... Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics.

Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

USA News Group News Commentary – The United States is poised for a transformative leap in AI innovation as President Trump unveiled a private massive $500 billion investment ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...